Document is current

Article History

Received: 27 March 2025

Accepted: 17 December 2025

First Online: 29 May 2026

Competing interests

: Meritxell Bellet has declared an advisor role or consulting from Novartis, Pfizer, Lilly, Stemline Menarini and travel expenses from Pfizer and Roche. Milana Bergamino has declared an advisor role or consulting fees from Lilly Eli, Pfizer, Novartis, Daiichi Sankyo and Astra Zeneca and travel expenses from Novartis and Astra Zeneca. She also declares salary from Fundación BBVA grant Joan Rodés-Josep Baselga 2024-2027. Claudette Falato has been employed by AstraZeneca since September 2023, however involvement in this study predates this employment and AstraZeneca was not involved in the study. Tomás Pascual reports having received Fees for Non-CME Services Received Directly from Commercial Interest ortheir Agents (e.g., speakers' bureaus) from Astra Zeneca, Consulting Fees (e.g., advisory boards) from Novartis, andFees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) from Pfizer. Xavier Gonzalez-Farré has declared personal honoraria from Astra Zeneca, Pierre Fabre, Novartis, Roche and travelexpenses from Astra Zeneca, Roche, Lilly Aleix Prat has declared personal honoraria from Pfizer, Novartis, Roche, Reveal Genomics, Lilly and Daiichi Sankyo, travel, accommodations, and expenses paid by Daiichi Sankyo, research funding from Roche, AstraZeneca, RevealGenomics and Novartis, consulting/advisory role for Reveal Genomics, Roche, Novartis, Pfizer, and Daiichi Sankyo,Inc. outside the submitted work. Cristina Saura has declared personal honoraria as consulting/advisory from AstraZeneca, AX'Consulting, Byondis B.V, Daiichi Sankyo, Eisai, Exact Sciences, Exeter Pharma, F.Hoff mann-La Roche Ltd, Lilly, MediTech, Merck Sharp & Dohme, Novartis, Pfizer, Philips, Pierre Fabre, PintPharma, Puma Biotechnology, SeaGen, and Zymeworks. The other authors declare no conflict of interest.